Yurpeak India: Cipla Tirzepatide for Diabetes & Weight Loss
Yurpeak is the second tirzepatide brand in India — the same molecule as Mounjaro, manufactured by Eli Lilly, distributed by Cipla. Prescribed at Nirvana Clinic, Greater Noida, by Dr. Manuj Sondhi (MRCP UK) for Type 2 Diabetes and chronic weight management.
What Is Yurpeak?
Yurpeak is tirzepatide — the same active drug as Mounjaro. In October 2025, Eli Lilly signed a distribution and promotion agreement with Cipla to launch a second brand of tirzepatide in India. The drug officially launched in December 2025.
The molecule is identical to Mounjaro. The pricing is identical. The difference is distribution reach — Cipla brings its deep Tier-2 and Tier-3 pharmacy network into play, making tirzepatide more accessible to patients outside the metros.
Yurpeak is approved by the DCGI for two indications: Type 2 Diabetes (improving blood sugar control) and chronic weight management (in adults with BMI ≥27 with weight-related conditions, or BMI ≥30). It is administered as a once-weekly subcutaneous injection via prefilled KwikPen.
Key Facts at a Glance
- Brand: Yurpeak
- Manufacturer: Eli Lilly & Company
- Distributor: Cipla Limited
- Active ingredient: Tirzepatide
- Drug class: Dual GIP / GLP-1 receptor agonist
- Format: KwikPen prefilled injector (no vials)
- Doses available: 2.5, 5, 7.5, 10, 12.5, 15 mg
- Frequency: Once weekly, subcutaneous
- Indications: Type 2 Diabetes + Chronic Weight Management
- Prescription status: Rx only
- Country of origin: Italy
- Indian launch: December 2025
Yurpeak vs Mounjaro vs Wegovy
All three are GLP-1 receptor agonist injections approved for weight loss and/or diabetes in India. Here is how they compare.
- Drug: Tirzepatide
- Mechanism: Dual GLP-1 + GIP
- Format: KwikPen only
- Doses: 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg
- Price: ₹13,125 – ₹25,781 / month
- Indication: T2D + Weight
- Distribution: Cipla wide reach (Tier-2/3)
- Drug: Tirzepatide (same as Yurpeak)
- Mechanism: Dual GLP-1 + GIP
- Format: KwikPen + Vials
- Doses: 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg
- Price: ₹13,125 – ₹27,500 / month
- Indication: T2D + Weight
- Distribution: Lilly's direct channel
- Drug: Semaglutide
- Mechanism: GLP-1 only
- Format: FlexTouch prefilled pen
- Doses: 0.25 / 0.5 / 1 / 1.7 / 2.4 mg
- Price: ₹10,850 – ₹24,500 / month
- Indication: Weight management primary
- Distribution: Novo's direct network
Which one is right for you?
Choose Yurpeak or Mounjaro if you have Type 2 Diabetes that needs better control, or if you've not responded well enough to semaglutide. Clinical trials show tirzepatide delivers more weight loss than semaglutide at maximum doses (SURMOUNT-1 trial: ~21% body weight reduction with tirzepatide 15 mg vs ~15% with semaglutide 2.4 mg in STEP-1).
Choose Wegovy if your primary goal is weight loss without diabetes, you prefer semaglutide's lower starting cost, or you've tolerated semaglutide well in the past. The honest answer comes from a metabolic assessment — there is no universal "best" GLP-1.
Yurpeak Cost in India (2026)
Price per KwikPen (4 weekly doses = approximately 1 month supply). Prices are MRP from Eli Lilly/Cipla via licensed pharmacies and may vary by location.
| Dose Strength | KwikPen Type | Monthly Cost (₹) | Typical Use |
|---|---|---|---|
| 2.5 mg | Starting dose | ₹13,125 | First 4 weeks — initiation |
| 5 mg | Titration | ₹16,406 | Weeks 5–8 |
| 7.5 mg | Maintenance | ₹19,688 | Weeks 9–12 if tolerated |
| 10 mg | Maintenance | ₹21,875 | Weeks 13–16 if needed |
| 12.5 mg | Higher maintenance | ₹24,063 | For higher weight-loss goals |
| 15 mg | Maximum dose | ₹25,781 | Maximum approved dose |
Note: Pricing is from publicly listed MRP as of May 2026. Actual price at your local pharmacy may vary slightly. Dose escalation is gradual and not every patient reaches 15 mg — many maintain weight loss at lower doses. At Nirvana Clinic, we titrate based on individual tolerance and response.
Starting Yurpeak — How It Works at Nirvana Clinic
Yurpeak therapy is not a one-shot prescription. Done properly, it follows a structured medical pathway under physician supervision.
Critical: Patients on tirzepatide can lose significant muscle mass, especially at higher doses. Our clinic includes a structured muscle-protection protocol — protein targets, resistance-training plan, and DEXA monitoring when indicated.
Read GLP-1 Muscle Loss Guide →Who Should — and Who Should Not — Take Yurpeak
- Adults with Type 2 Diabetes and HbA1c above 7.0%
- Adults with BMI ≥30 (obesity)
- Adults with BMI ≥27 plus weight-related complications (hypertension, dyslipidaemia, sleep apnoea)
- Patients with PCOS-related insulin resistance
- Patients who did not respond well to lifestyle changes alone
- Patients prepared to commit to weekly injections for 6–12 months minimum
- Patients with normal kidney function (eGFR > 30)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Severe gastroparesis (delayed gastric emptying)
- Pregnancy or breastfeeding
- Type 1 Diabetes (not approved for this)
- Diabetic ketoacidosis
- Severe kidney disease (eGFR < 30) — caution required
Yurpeak Side Effects — What to Expect
Like all GLP-1 receptor agonists, tirzepatide has common and rare side effects. Most are manageable with proper titration.
Common Side Effects (most settle in 2-4 weeks)
- Nausea — 25% of patients; usually first 2-4 weeks
- Vomiting — 8-10%
- Diarrhoea — 16%
- Constipation — 9%
- Decreased appetite — expected (this is partly how the drug works)
- Fatigue — 5-7%
- Injection site reactions — mild, usually self-limiting
Rare But Serious — Watch For
- Pancreatitis — severe persistent abdominal pain; stop and see doctor
- Gallbladder problems — gallstones, cholecystitis
- Kidney problems — usually due to dehydration from vomiting/diarrhoea
- Severe hypoglycaemia — when used with insulin or sulfonylureas
- Allergic reactions — rare; rash, swelling
- Diabetic retinopathy worsening — in pre-existing cases
- Theoretical thyroid risk — from rodent studies; not confirmed in humans
Dr. Manuj Sondhi — Yurpeak & Tirzepatide Specialist
Dr. Manuj Sondhi
MRCP (UK) · MD · DNB · Senior Consultant Nirvana Clinic · Visiting Consultant Fortis Hospital Greater Noida · MCI 12-42985 · ORCID 0009-0007-0394-9480 · 15+ Years
One of Greater Noida's few MRCP UK-certified diabetologists, Dr. Manuj has prescribed tirzepatide (Mounjaro and now Yurpeak) since its India launch in 2025. His GLP-1 protocol is one of the few in NCR that explicitly includes body composition monitoring, protein-targeted nutrition, and resistance-training prescription to protect muscle mass during weight loss — addressing the most common quality-of-life concern with these drugs.
He sees patients from across NCR for Yurpeak initiation, dose optimisation, switching from Mounjaro or Wegovy, and management of side effects.
Frequently Asked Questions About Yurpeak
What is Yurpeak?▼
Yurpeak is the second tirzepatide brand in India, launched in December 2025 by Cipla under a distribution agreement with Eli Lilly. It contains the same active molecule as Mounjaro — tirzepatide — and is approved for Type 2 Diabetes and chronic weight management. It is available as a KwikPen prefilled injector in six dose strengths.
How is Yurpeak different from Mounjaro?▼
The active drug is identical — both are tirzepatide manufactured by Eli Lilly. The differences are in distribution and format. Yurpeak is distributed by Cipla, giving it wider reach in Tier-2 and Tier-3 Indian cities. Yurpeak is available only in KwikPen format, whereas Mounjaro is available in both KwikPen and vials. Pricing is identical between the two brands.
How much does Yurpeak cost in India?▼
Yurpeak is priced at ₹13,125 per month for the 2.5 mg starting dose, ₹16,406 for 5 mg, and rises to approximately ₹25,781 for the 15 mg maximum dose. Each KwikPen contains 4 weekly doses (1 month supply). See the full pricing table above. Prices may vary slightly by pharmacy.
Is Yurpeak available in Greater Noida?▼
Yes. Yurpeak is available through licensed pharmacies in Greater Noida and surrounding NCR areas with a valid prescription. Online pharmacies including 1mg also deliver to Greater Noida. Dr. Manuj Sondhi (MRCP UK) prescribes Yurpeak at Nirvana Clinic, Greater Noida, when clinically appropriate.
Do I need a prescription for Yurpeak?▼
Yes. Yurpeak is a prescription-only medication in India. Self-purchase without a doctor's prescription is illegal and unsafe. Tirzepatide can cause significant side effects and requires dose titration and metabolic monitoring under medical supervision.
Who can prescribe Yurpeak?▼
Yurpeak is typically prescribed by diabetologists, endocrinologists, internal medicine physicians, and bariatric specialists. At Nirvana Clinic, Yurpeak is prescribed by Dr. Manuj Sondhi (MRCP UK, Senior Consultant), who specialises in GLP-1 therapy and metabolic medicine.
What are the common side effects of Yurpeak?▼
Common side effects include nausea, vomiting, diarrhoea, constipation, decreased appetite, and injection-site reactions. Most settle within 2 to 4 weeks as the body adjusts and with proper dose titration. Serious but rare risks include pancreatitis, gallbladder problems, and a theoretical thyroid concern. A proper medical assessment screens for contraindications before starting.
Is Yurpeak better than Wegovy or Ozempic?▼
Yurpeak (tirzepatide) targets both GLP-1 and GIP receptors, whereas Wegovy and Ozempic (semaglutide) target GLP-1 only. Clinical trials show tirzepatide typically produces greater weight loss than semaglutide at maximum doses (~21% vs ~15% body weight reduction). Which drug is right depends on individual factors including weight loss goal, diabetes status, side-effect profile, and cost. See our Mounjaro vs Wegovy comparison for a detailed breakdown.
Can I switch from Mounjaro to Yurpeak?▼
Yes, switching is straightforward because both brands contain identical tirzepatide manufactured by Eli Lilly. Continue at the same dose strength when switching. Discuss with your doctor before changing brands, especially if you're on a specific dose protocol or experiencing side effects.
Does Yurpeak cause muscle loss?▼
Yes — all GLP-1 receptor agonists, including tirzepatide, cause some muscle loss along with fat loss during rapid weight reduction. Clinical trials show approximately 25% of total weight lost on tirzepatide can be lean mass if no countermeasures are taken. This is a significant concern, especially for Indian patients with already lower baseline muscle mass. At Nirvana Clinic, our protocol includes protein-targeted nutrition (1.2–1.6 g/kg/day) and resistance training. Read our detailed guide on GLP-1 muscle loss.
How do I book a Yurpeak consultation at Nirvana Clinic?▼
Call or WhatsApp Dr. Manuj Sondhi at +91 88002 62767. Nirvana Clinic is at Shop GF-93, Sun Twilight Mall, Opposite Delta 1 Metro Station, Greater Noida 201308. Open Monday to Saturday, 9 AM to 8 PM. The initial consultation includes metabolic assessment, eligibility screening, and a personalised tirzepatide treatment plan.
Other GLP-1 and Weight Loss Services
Considering Yurpeak? Get a Proper Assessment First.
Tirzepatide is a powerful medication. Done right, it transforms metabolic health.
Done wrong, it causes preventable muscle loss and side effects.
Book a Yurpeak eligibility consultation with Dr. Manuj Sondhi (MRCP UK).